An antibody–drug conjugate targeting HER2 that is internalized after binding, releasing the cytotoxic payload MMAE to disrupt microtubules and induce tumor cell apoptosis (with potential bystander effect).
Anti‑HER2 monoclonal antibody linked to MMAE. After binding HER2 on tumor cells, the ADC is internalized and releases MMAE, which disrupts microtubules (tubulin polymerization inhibition), causing cell-cycle arrest and apoptosis, with potential bystander killing of adjacent cells.
YES
DIRECT
ADC binds HER2, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing mitotic arrest and apoptosis (with possible bystander effect).
An antibody–drug conjugate targeting HER2 that is internalized after binding, releasing the cytotoxic payload MMAE to disrupt microtubules and induce tumor cell apoptosis (with potential bystander effect).
Anti‑HER2 monoclonal antibody linked to MMAE. After binding HER2 on tumor cells, the ADC is internalized and releases MMAE, which disrupts microtubules (tubulin polymerization inhibition), causing cell-cycle arrest and apoptosis, with potential bystander killing of adjacent cells.
NO
INDIRECT
The ADC targets HER2 for uptake; once internalized, it releases MMAE, which binds beta-tubulin and inhibits microtubule polymerization, causing mitotic arrest and apoptosis. Beta-tubulin expression alone is not sufficient for targeting or killing.
A HER2-targeted antibody-drug conjugate in which an anti-HER2 monoclonal antibody delivers an intracellular cytotoxic payload after HER2 binding and internalization; may also engage Fc-mediated effector functions.
An anti-HER2 IgG1 monoclonal antibody binds HER2 on tumor cells, is internalized, and releases a camptothecin-derived topoisomerase I inhibitor via a cleavable linker, stabilizing TOP1-DNA complexes, causing DNA strand breaks, blocking replication, and inducing apoptosis; the antibody may also mediate Fc-dependent effector functions (e.g., ADCC).
YES
DIRECT
The anti-HER2 ADC binds HER2, is internalized, and releases a camptothecin-derived topoisomerase I inhibitor that causes DNA damage and apoptosis; the IgG1 may also induce Fc-mediated ADCC.
A HER2-targeted antibody-drug conjugate in which an anti-HER2 monoclonal antibody delivers an intracellular cytotoxic payload after HER2 binding and internalization; may also engage Fc-mediated effector functions.
An anti-HER2 IgG1 monoclonal antibody binds HER2 on tumor cells, is internalized, and releases a camptothecin-derived topoisomerase I inhibitor via a cleavable linker, stabilizing TOP1-DNA complexes, causing DNA strand breaks, blocking replication, and inducing apoptosis; the antibody may also mediate Fc-dependent effector functions (e.g., ADCC).
NO
INDIRECT
The ADC targets HER2 for uptake; once internalized, it releases a camptothecin payload that inhibits TOP1, stabilizing TOP1–DNA complexes, causing DNA breaks and apoptosis. TOP1 expression alone does not direct drug delivery or selective killing.
A TROP2-targeted antibody-drug conjugate comprising an anti-TROP2 monoclonal antibody linked to a cytotoxic payload that is delivered to TROP2-expressing tumor cells upon internalization.
Anti-TROP2 monoclonal antibody linked to a cytotoxic payload; binds TROP2 on tumor cells, is internalized, and releases the payload intracellularly to induce tumor cell death (e.g., via DNA damage or microtubule disruption), with potential Fc-mediated effector contributions.
YES
DIRECT
The anti-TROP2 ADC binds TROP2, is internalized, and releases a cytotoxic payload that kills the cell (e.g., via DNA damage or microtubule disruption); Fc-mediated ADCC/CDC may also contribute.